69 results
6-K
EX-99.1
IPHA
Innate Pharma
14 May 24
Innate Pharma Reports First Quarter 2024 Business Update And Financial Results
6:07am
of independent experts, determined to be related to aggressive disease progression and lacutamab unrelated.
Peripheral T Cell lymphoma (PTCL
6-K
EX-99.1
5xx8aj21nx vwxj11q6q
21 Mar 24
Summary of Consolidated Financial Statements and Notes
9:20am
6-K
EX-99.1
laq98 b0w5ld44bh
21 Mar 24
Innate Pharma reports Full Year 2023 Financial Results and Business Update
6:01am
6-K
EX-5.1
hyn3quxowx6ho8vkr
6 Feb 24
Current report (foreign)
5:05pm
6-K
EX-1.1
7yal78edu 7rb
6 Feb 24
Current report (foreign)
5:05pm
424B5
lmfmn38wgt
6 Feb 24
Prospectus supplement for primary offering
5:00pm
6-K
zcalga1xr0hpse zih
5 Jan 24
Innate Pharma S.a. 6-K
6:09am
6-K
EX-99.1
ttslvipoc9d 33yzb2mu
4 Jan 24
FDA lifts partial clinical hold on lacutamab clinical programFatal case related to disease progression and unrelated to the treatment
6:01am
F-3
EX-23.1
z1nnunrg
20 Dec 23
Shelf registration (foreign)
4:45pm
F-3
lu7xhhfpd
20 Dec 23
Shelf registration (foreign)
4:45pm
F-3
EX-3.1
sgutmcbcackl
20 Dec 23
Shelf registration (foreign)
4:45pm
F-3
EX-5.1
kbmc2qdik9 ba
20 Dec 23
Shelf registration (foreign)
4:45pm
6-K
EX-1.1
n0hqi did
26 Apr 23
Current report (foreign)
4:02pm
424B5
rycq wikr6h
26 Apr 23
Prospectus supplement for primary offering
4:01pm
20-F/A
EX-4.9
z28k85ut4ng88jcz8muv
20 Apr 23
Annual report (foreign) (amended)
8:47am